Alkermes plc. (ALKS) Free cash flow
- Free cash flow · 12 months (USD): Value $221.65M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 13.29%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $221.65M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $251.18M − $29.53M ≈ $221.65M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 13.29% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $221.65M ÷ $1.67B × 100 ≈ 13.29% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $251.18M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 3.80× | Operating cash flow / net income. Period ending 2026-06-30. $251.18M ÷ $66.16M ≈ 3.80× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 251.18M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 29.53M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 221.65M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.67B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 66.16M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $221.65M | (m) | $251.18M | $29.53M | (m) | $1.67B | (m) | $66.16M | (m) | (m) | 13.29% | 3.80× |
| 2026-03-31 | $221.80M | (m) | $256.20M | $34.40M | (m) | $1.56B | (m) | $152.76M | (m) | (m) | 14.20% | 1.68× |
| 2025-12-31 | $480.33M | (m) | $520.75M | $40.42M | (m) | $1.48B | (m) | $241.66M | (m) | (m) | 32.55% | 2.15× |
| 2025-09-30 | $490.87M | (m) | $541.08M | $50.21M | (m) | $1.52B | (m) | $338.83M | (m) | (m) | 32.27% | 1.60× |
| 2025-06-30 | $479.84M | (m) | $521.00M | $41.16M | (m) | $1.51B | (m) | $348.45M | (m) | (m) | 31.88% | 1.50× |
| 2025-03-31 | $481.57M | (m) | $516.83M | $35.25M | (m) | $1.51B | (m) | $352.71M | (m) | (m) | 31.81% | 1.47× |
| 2024-12-31 | $405.64M | (m) | $439.12M | $33.48M | (m) | $1.56B | (m) | $367.07M | (m) | (m) | 26.04% | 1.20× |
| 2024-09-30 | $315.22M | (m) | $355.96M | $40.74M | (m) | $1.51B | (m) | $333.35M | (m) | (m) | 20.94% | 1.07× |
| 2024-06-30 | $327.15M | (m) | $374.08M | $46.94M | (m) | $1.51B | (m) | $288.72M | (m) | (m) | 21.70% | 1.30× |
| 2024-03-31 | $394.23M | (m) | $443.76M | $49.53M | (m) | $1.73B | (m) | $434.43M | (m) | (m) | 22.84% | 1.02× |
| 2023-12-31 | $353.31M | (m) | $401.35M | $48.05M | (m) | $1.66B | (m) | $355.76M | (m) | (m) | 21.24% | 1.13× |
| 2023-09-30 | $254.12M | (m) | $295.16M | $41.05M | (m) | $1.59B | (m) | $214.72M | (m) | (m) | 15.98% | 1.37× |
| 2023-06-30 | $159.01M | (m) | $196.08M | $37.07M | (m) | $1.46B | (m) | $102.99M | (m) | (m) | 10.88% | 1.90× |
| 2023-03-31 | $-59.26M | (m) | $-21.94M | $37.32M | (m) | $1.12B | (m) | $-164.21M | (m) | (m) | -5.29% | 0.13× |
| 2022-12-31 | $-17.21M | (m) | $21.04M | $38.26M | (m) | $1.11B | (m) | $-158.27M | (m) | (m) | -1.55% | -0.13× |
| 2022-09-30 | $14.13M | (m) | $51.02M | $36.89M | (m) | $1.13B | (m) | $-129.14M | (m) | (m) | 1.25% | -0.40× |
| 2022-06-30 | $101.94M | (m) | $133.17M | $31.23M | (m) | $1.17B | (m) | $-94.15M | (m) | (m) | 8.69% | -1.41× |
| 2022-03-31 | $140.71M | (m) | $168.54M | $27.82M | (m) | $1.20B | (m) | $-61.65M | (m) | (m) | 11.72% | -2.73× |
| 2021-12-31 | $73.69M | (m) | $101.72M | $28.02M | (m) | $1.17B | (m) | $-48.17M | (m) | (m) | 6.28% | -2.11× |
| 2021-09-30 | $113.24M | (m) | $138.04M | $24.80M | (m) | $1.13B | (m) | $-91.68M | (m) | (m) | 10.03% | -1.51× |
| 2021-06-30 | $89.07M | (m) | $115.46M | $26.39M | (m) | $1.10B | (m) | $-62.83M | (m) | (m) | 8.10% | -1.84× |
| 2021-03-31 | $47.56M | (m) | $77.97M | $30.41M | (m) | $1.04B | (m) | $-94.63M | (m) | (m) | 4.56% | -0.82× |
| 2020-12-31 | $40.62M | (m) | $82.84M | $42.22M | (m) | $1.04B | (m) | $-110.86M | (m) | (m) | 3.91% | -0.75× |
| 2020-09-30 | $-11.18M | (m) | $57.57M | $68.75M | (m) | $1.17B | (m) | $-73.57M | (m) | (m) | -0.95% | -0.78× |
| 2020-06-30 | $-53.43M | (m) | $28.34M | $81.77M | (m) | $1.16B | (m) | $-126.32M | (m) | (m) | -4.60% | -0.22× |
| 2020-03-31 | $-77.51M | (m) | $9.59M | $87.10M | (m) | $1.19B | (m) | $-138.88M | (m) | (m) | -6.49% | -0.07× |
| 2019-12-31 | $-18.86M | (m) | $72.08M | $90.94M | (m) | $1.17B | (m) | $-196.62M | (m) | (m) | -1.61% | -0.37× |
| 2019-09-30 | $13.96M | (m) | $90.52M | $76.56M | (m) | $1.07B | (m) | $-200.98M | (m) | (m) | 1.30% | -0.45× |
| 2019-06-30 | $19.48M | (m) | $93.03M | $73.55M | (m) | $1.07B | (m) | $-182.54M | (m) | (m) | 1.82% | -0.51× |
| 2019-03-31 | $73.75M | (m) | $148.33M | $74.58M | (m) | $1.09B | (m) | $-173.20M | (m) | (m) | 6.75% | -0.86× |
| 2018-12-31 | $29.85M | (m) | $99.28M | $69.43M | (m) | $1.09B | (m) | $-139.31M | (m) | (m) | 2.73% | -0.71× |
| 2018-09-30 | $5.02M | (m) | $74.68M | $69.66M | (m) | $1.05B | (m) | (m) | (m) | (m) | 0.48% | (m) |
| 2018-06-30 | $-5.39M | (m) | $60.68M | $66.06M | (m) | $1.02B | (m) | (m) | (m) | (m) | -0.53% | (m) |
| 2018-03-31 | $-54.30M | (m) | $6.10M | $60.40M | (m) | $936.75M | (m) | (m) | (m) | (m) | -5.80% | (m) |
| 2017-12-31 | $-32.11M | (m) | $19.19M | $51.30M | (m) | $903.37M | (m) | $-157.94M | (m) | (m) | -3.55% | -0.12× |
| 2017-09-30 | $-52.51M | (m) | $-9.16M | $43.35M | (m) | $841.52M | (m) | (m) | (m) | (m) | -6.24% | (m) |
| 2017-06-30 | $-55.94M | (m) | $-13.91M | $42.03M | (m) | $804.37M | (m) | (m) | (m) | (m) | -6.95% | (m) |
| 2017-03-31 | $-61.37M | (m) | $-20.34M | $41.03M | (m) | $780.70M | (m) | (m) | (m) | (m) | -7.86% | (m) |
| 2016-12-31 | $-107.46M | (m) | $-63.80M | $43.66M | (m) | $745.69M | (m) | $-208.44M | (m) | (m) | -14.41% | 0.31× |
| 2016-09-30 | $-118.88M | (m) | $-68.94M | $49.94M | (m) | $695.28M | (m) | (m) | (m) | (m) | -17.10% | (m) |
| 2016-06-30 | $-163.53M | (m) | $-113.12M | $50.40M | (m) | $667.69M | (m) | (m) | (m) | (m) | -24.49% | (m) |
| 2016-03-31 | $-153.83M | (m) | $-99.65M | $54.18M | (m) | $623.89M | (m) | (m) | (m) | (m) | -24.66% | (m) |
| 2015-12-31 | $-93.24M | (m) | $-40.36M | $52.88M | (m) | $628.34M | (m) | $-227.16M | (m) | (m) | -14.84% | 0.18× |
| 2015-09-30 | $-79.19M | (m) | $-29.13M | $50.05M | (m) | $640.40M | (m) | (m) | (m) | (m) | -12.37% | (m) |
| 2015-06-30 | $-54.46M | (m) | $-7.50M | $46.97M | (m) | $647.74M | (m) | (m) | (m) | (m) | -8.41% | (m) |
| 2015-03-31 | $-21.99M | (m) | $16.69M | $38.68M | (m) | $649.79M | (m) | (m) | (m) | (m) | -3.38% | (m) |
| 2014-12-31 | $-22.51M | (m) | $11.14M | $33.65M | (m) | $618.79M | (m) | $-30.06M | (m) | (m) | -3.64% | -0.37× |
| 2014-09-30 | $5.42M | (m) | $35.60M | $30.18M | (m) | $598.11M | (m) | (m) | (m) | (m) | 0.91% | (m) |
| 2014-06-30 | $57.91M | (m) | $84.78M | $26.87M | (m) | $577.92M | (m) | (m) | (m) | (m) | 10.02% | (m) |
| 2014-03-31 | $64.01M | (m) | $88.75M | $24.74M | (m) | $563.12M | (m) | (m) | (m) | (m) | 11.37% | (m) |
| 2013-12-31 | $120.21M | (m) | $147.53M | $27.31M | (m) | $596.33M | (m) | (m) | (m) | (m) | 20.16% | (m) |
| 2013-09-30 | $115.41M | (m) | $135.62M | $20.21M | (m) | $577.76M | (m) | (m) | (m) | (m) | 19.98% | (m) |
| 2013-06-30 | $124.89M | (m) | $144.00M | $19.11M | (m) | $561.94M | (m) | (m) | (m) | (m) | 22.22% | (m) |
| 2013-03-31 | $104.33M | (m) | $126.55M | $22.22M | (m) | $575.55M | (m) | $24.98M | (m) | (m) | 18.13% | 5.07× |
| 2012-12-31 | $64.44M | (m) | $86.53M | $22.09M | (m) | $542.60M | (m) | (m) | (m) | (m) | 11.88% | (m) |
| 2012-09-30 | $33.58M | (m) | $58.12M | $24.54M | (m) | $532.33M | (m) | (m) | (m) | (m) | 6.31% | (m) |
| 2012-06-30 | $-11.72M | (m) | $11.08M | $22.80M | (m) | $480.33M | (m) | (m) | (m) | (m) | -2.44% | (m) |
| 2012-03-31 | $-19.47M | (m) | $-2.48M | $16.99M | (m) | $389.98M | (m) | $-113.68M | (m) | (m) | -4.99% | 0.02× |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $-15.31M | (m) | $-5.91M | $9.40M | (m) | $186.64M | (m) | $-45.54M | (m) | (m) | -8.20% | 0.13× |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $-28.03M | (m) | $-12.25M | $15.79M | (m) | $178.28M | (m) | $-39.63M | (m) | (m) | -15.72% | 0.31× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |